Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
用长链NY-ESO-1肽和CpG-B对III/IV期黑色素瘤患者进行疫苗接种,可诱导产生强烈的CD8(+)和CD4(+) T细胞反应,这些反应具有多种特异性,包括一种新型的DR7限制性表位。
期刊:Oncoimmunology
影响因子:6.3
doi:10.1080/2162402X.2016.1216290
Baumgaertner, P; Costa Nunes, C; Cachot, A; Maby-El Hajjami, H; Cagnon, L; Braun, M; Derré, L; Rivals, J-P; Rimoldi, D; Gnjatic, S; Abed Maillard, S; Marcos Mondéjar, P; Protti, M P; Romano, E; Michielin, O; Romero, P; Speiser, D E; Jandus, C
T细胞
T细胞
CD4
CD8
免疫/内分泌
黑色素瘤
细胞生物学